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Synthesis and characterisation of macrocycles containing both tetrazole and
pyridine functionalities
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Abstract

The syntheses of tetra-tetrazole macrocycles containing at least one 2,6-bis(tetrazole)pyridine
unit, linked by a variety of n-alkyl (n = 3, 5, 7 or 9 carbon atoms) chain lengths, are described.
There has been no previous incorporation of the pyridine moiety into a tetra-tetrazolophane
macrocycle. The crystal structure of one such tetra-tetrazole macrocycle has also been
structurally characterised and revealed a bowl-shaped conformation.
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Introduction

There are many articles and reviews on tetrazoles in the literature, including their use as
carboxylic acid bioisosteres in drug discovery and as functional ligands in coordination
chemistry.1-5 The development of “click” chemistry methodology, as described by Sharpless and
co-workers,6,7 has resulted in a recent increase in tetrazole structures, which suggests that
molecular recognition studies of tetrazoles will become increasingly important.8-15 We are
interested in tetrazoles as precursors for the formation of new functionalised polytetrazole
macrocycles, which could find application, for example, as sensors or in molecular recognition.
We have previously reported the synthesis and structural characterisation of tetra-tetrazole
macrocycles from 1,2-, 1,3- and 1,4-dicyanobenzene derivatives as well as the first example of a
host-guest interaction between a tetra-tetrazole macrocycle and a solvent molecule.16-18 Previous
work in our group has shown that the use of odd-numbered carbon chains gave higher yields than
when even-numbered chains were used.18 This paper focuses on the synthesis and
characterisation of bis-tetrazoles from 2,6-pyridinedicarbonitrile (1), their n-alkyl halide
derivatives (where n = 3, 5, 7 or 9), and their resulting tetra-tetrazole macrocycles (see Scheme
1). To our knowledge, there has been no previous incorporation of the pyridine moiety into a
tetra-tetrazolophane macrocycle. The X-ray crystal structure of one such macrocyclic derivative
(7c), which is obtained from the reaction of 3c with 1,3-bis(tetrazol-5-yl)benzene (6), is also
described.
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Scheme 1. Reagents and conditions: (i) NaN3, NH4Cl, LiCl, DMF, 110 oC, 10 h; (ii) 1,ndibromoalkane (n = 3, 5, 7, 9), Et3N, MeOH, ∆, 24 h; (iii) 2, K2CO3, DMF, 75 oC, 24 h; iv) 6,
K2CO3, DMF, 75 oC, 24 h.

Results and Discussion

Syntheses and characterisation of bis-tetrazoles

The reaction of 2,6-pyridinedicarbonitrile (1) with sodium azide was carried out, following a
similar procedure to that we have previously described,19 to give 2,6-di(2H-tetrazol-5-yl)pyridine
(2) in good yield. The IR spectrum of 2 showed the indicative loss of the nitrile and azide bands
at ca. 2200 and ca. 2060 cm-1, respectively. The 1H NMR spectrum of 2 showed a multiplet at
8.32 ppm due to the pyridyl ring proton signals, and a broad singlet at 3.56 ppm due to the NH
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proton. The 13C NMR spectrum confirmed the formation of the tetrazole system with the signal at
158.5 ppm, indicative of the tetrazole moiety.16-19
The alkylation of 2 was carried out using the appropriate α,ω-dibromoalkane in the presence of
triethylamine as base in methanol for three hours at reflux temperature. In each case, after cooling
and reaction work-up, only two products were obtained, which were purified by column
chromatography on silica gel. These products were the N2,N1' (major) (3a-d) and N2,N2' (minor)
(4a-d) di-alkylated systems. The melting points of the symmetric and asymmetric products
differed. It was observed that the symmetric analogues N2,N2' had slightly higher melting point
values, which may have been due to the symmetric system experiencing greater intermolecular
bonding.

The range of asymmetric product yields (3a-d) varied from 17%-37% (see experimental) and
were considerably higher than the symmetric products (4a-d). It was observed that as the chain
length increased the yield also increased. This may be due to the possibility of the species
containing shorter chains forming polymeric adducts. The IR spectra of 3a-d showed the
characteristic bands of the tetrazole at 1668, 1523 and 1254 cm-1 and the >C=N- band of the
pyridine at 1458 cm-1 respectively. The 1H NMR spectra of 3a-d clearly showed the asymmetry
that is present in the products. The aromatic protons that are ortho to the tetrazole rings are both
split into two separate doublets at 8.50 ppm, beside the N1 tetrazole ring, and at 8.38 ppm for the
N2 tetrazole ring of 3a. The pseudo-triplet signal for the remaining proton on the pyridine ring at
8.12 ppm is not affected by asymmetry, probably due to its distance from the point of asymmetry.
The methylene groups directly attached to the tetrazole ring appear as two separate triplets in the
1

H NMR spectra of 3a-d with the N1-CH2 triplet being observed at 5.25 ppm and the N2-CH2

signal being observed at 4.96 ppm in 3a. The signal associated with the CH2Br appeared at ~3.4
ppm as a multiplet in all compounds in the series apart from compound 3a, where two triplets at
3.62 ppm and 3.51 ppm (N1 and N2) were observed. This was probably due to the short distance
from the N1 and N2 alkylated tetrazoles to the CH2Br. As a comparison, in the 1H NMR spectra
of the 1,3-bis[(bromoalkylyl)tetrazol-5-yl]benzene (2-N, 2-N’),18 the N2-CH2 signals appear at
~4.70 ppm while those for the CH2Br appear at ~3.40 ppm. All other methylene signals can be
observed as multiplets between 2.1-1.3 ppm. The
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C NMR spectra of 3a-d also showed the

asymmetric nature of the product with two tetrazole peaks at ~164 ppm for the N2 substituted
tetrazole and ~151 ppm for the N1 substituted tetrazole.
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The 1H NMR spectra for the symmetric bis-tetrazoles 4a-d are much simpler that those observed
for the asymmetric bis-tetrazoles 3a-d, just discussed. The aromatic protons, ortho to the tetrazole
rings, appear as as a single doublet at ~8.36 ppm while the remaining proton on the pyridine ring
appears as a triplet at ~8.38 ppm. Furthermore, the methylene groups directly attached to the
tetrazole ring now appear as a single triplet in the 1H NMR spectra of 4a-d at 4.95 ppm for 4a
and at ~4.75 ppm for 4b-d. The

13

C NMR spectra confirmed the symmetric nature of the

compounds with a signal at 164.4 ppm, due to the tetrazoles being substituted in the N2 position.
The IR spectra of 4a-d were very similar to those of the asymmetric derivatives. Apart from the
NMR spectra, the other major difference between the asymmetric and symmetric derivatives was
in the yield of material recovered. The yield of the symmetric products 4a-d was surprisingly
low, falling in the range of 2-5 %. One possible reason for these low yields in the symmetric
cases may be the presence of a pyridinium salt, formed during the acidification work-up of the
bis-tetrazole derivative 2. Due to the difference in pKa between pyridine (ca. pKa 5.2) and
tetrazole (ca. pKa 4.5), it is believed that the pyridine nitrogen will be protonated. However, this
does not explain the difference in yield between the asymmetric and symmetric derivatives, as
this pyridinium salt would also have been present in the reaction.

X-Ray crystal structure of 3b

Crystals of compound 3b, suitable for an X-ray diffraction study, were obtained as colourless
plates by the diffusion method of chloroform in methanol. The diffraction data were of poor
quality but the significant features of the structure are clear. The structure confirmed the presence
of the pendant bromoalkyl groups substituted in the N2,N1' positions, see Figure 1.
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Figure 1. Molecular structure of 3b with displacement ellipsoids at the 50% probability level for
non-H atoms.

One of the tetrazole rings and the pyridine ring are almost co-planar, with the other tetrazole ring
being distinctly tilted relative to the other two rings. Both bromohexyl arms lie on the same face
of the pyridine ring. A - interaction between neighbouring molecules is observed and shown
in Figure 2.

Figure 2. Observed - interaction of 3b.

Synthesis of pyridyl-tetra-tetrazole macrocycles
6

Since the yields of the asymmetric alkylated bis-tetrazoles (3a-d) were substantially better than
those of the symmetric derivatives, it was decided to attempt the synthesis of an asymmetric
pyridine tetra-tetrazole macrocycle. When an asymmetric alkylated product (3a-d) was reacted
with 2,6-bis-(2H-tetrazol-5-yl)-pyridine (2) using previously reported conditions,18 a number of
products were observed by TLC analysis. However, these products could not be separated by
conventional chromatography methods. This may have been due to the likelihood of pyridine
macrocycles (N2,N1',N2'',N1''') and (N2,N1',N1'',N2''') having similar Rf values. The 1H NMR
spectra of the single spot by TLC for each of the tetra-tetrazole macrocycles (5a-d) were very
complicated but clearly showed signals for two macrocycles (N2,N1',N2'',N1''') and
(N2,N1',N1'',N2''').

We have previously reported the synthesis and structural characterisation of tetra-tetrazole
macrocycles from 1,2-, 1,3- and 1,4-dicyanobenzene derivatives, using alkyl linkers.16,18 The
cyclisation reaction, in all cases, formed predominantly the symmetric product, where the alkyl
chains are joined to the tetrazole moieties at the N2 position, with very little asymmetry being
observed. It was therefore postulated that if the asymmetric alkylated products (3a-d) were
clipped with 1,3-bis(tetrazol-5-yl)benzene (6) that one major product would be obtained, which
was the alkylation of the 2N,2N' positions of 1,3-bis(tetrazol-5-yl)benzene (see Experimental
section). The major products in all of these reactions were the (N2,N2',N2'',N1''') macrocycles
(7a-d), with high yields of ~40% in all cases, except in the case of 7d which is probably due to
the difficulty in forming the large ring system. The HRMS results obtained for the four products
(7a-d) confirmed the formation of the macrocycles.

The IR spectra of 7a-d were very similar to those of the alkylated precursors (3a-d) with
characteristic shifts for pyridine, tetrazole and phenyl ring systems being observed (see
Experimental). In the 1H NMR spectra of all the cyclisation products, the signal for the CH2Br at
~3.4 ppm had disappeared, and the accompanying loss of the CH2Br signal in the
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C NMR

1

spectra confirmed that cyclisation had occurred. The H NMR spectra of 7a-d have a complex
aromatic region. The signals in the 1H NMR spectrum of 7a at 8.41(s), 8.17(d) and 7.60(t) ppm
are due to the protons of the phenyl ring while those at 8.31(d), 8.04(d) and 7.91(t) ppm are due
to the protons on the pyridine ring. The aromatic regions in the 1H NMR spectra of 7b-d are
similar. The asymmetric nature of the macrocycle is observed by the appearance of two sets of
doublets for the pyridine protons ortho to the different tetrazole rings. This asymmetry also
7

manifests itself in the signals of the methylene groups attached to the tetrazole rings. A triplet is
observed at 5.30 ppm for the methylene protons attached to the tetrazole ring at N1. A multiplet
for the methylene protons attached to the symmetric 1,3-bis(tetrazol-5-yl)benzene is observed at
5.03 ppm. Another multiplet is observed at 4.74 ppm for the methylene group bonded to the
second tetrazole attached to the pyridine group. These two multiplets at 5.03 and 4.74 ppm are
not observed as the alkyl chain increases, presumably because the environment in which the
methylene groups attached to the N2-tetrazole becomes similar. In compounds 7b-d, a single
multiplet is observed at ca. 4.70 ppm, which accounts for the 6 protons associated with the N2CH2 substituted tetrazoles. The remaining alkyl protons appear at 1.67 ppm. With increased alkyl
chain length further multiplets can be observed at ca. 2.10 ppm.
The 13C NMR spectra of 7a-d confirmed the macrocyclic structure with three signals observed at
164.6, 164.2 and 163.9 ppm, respectively, for the N2-substituted tetrazoles. A single signal was
observed at 151.5 ppm for the N1-substituted tetrazole, confirming the substitution pattern of the
macrocycles. Furthermore, four peaks are observed for the methylene carbons adjacent to the
tetrazole nitrogens at 51.3, 50.4 and 49.4 ppm for the N2 substituted tetrazoles and 46.1 ppm for
the N1 substituted tetrazole.

X-Ray Crystal Structure of 7c

Crystals of 7c were obtained from chloroform solution, and the crystal structure confirms the
expected tetra-tetrazole macrocyclic structure, with three of the tetrazole rings substituted at the
N2 position and one tetrazole ring substituted at the N1 position, as suggested by

13

C NMR

spectroscopy (Figure 3). The structure also shows that N8 of one tetrazole ring and N9 of the
pyridine ring are potentially available for use as metal ion chelators.
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Figure 3. Molecular structure of 7c with displacement ellipsoids at the 50% probability level for
non-H atoms.

Bond lengths and angles are similar to other tetrazole macrocyclic compounds we have
previously reported.16,18 One striking difference between 7c and a macrocycle which contains two
phenyl rings, such as 8,16 is the overall geometry of both macrocycles, which is bowl-shaped in
the case of 7c (Figure 4) but is more step-like in 8 (Figure 5). This geometry change is likely to
be a packing effect due to the different alkyl chain lengths. Furthermore, there is now only one
 interaction present between the ring containing N10-N13 and its symmetry equivalent (under
symmetry operation 1-x, 1-y, z), with a centroid-centroid distance of 3.478 Å, which results in the
packing arrangement shown in Figure 7. This type of arrangement is different to that observed in
8 where adjacent macrocycles are arranged so that one benzene-tetrazole unit lies over the cavity
of the adjacent macrocycle (Figure 5), forming a local stacking arrangement.

Figure 4. Side view of 7c.
9

Figure 5. Molecular structure of 8 showing displacement ellipsoids at the 50% probability level
for non-H atoms (left), and a stacking interaction between adjacent macrocycles in 8 (right).16

Figure 6. Unit cell of 7c viewed down the a axis, showing the packing arrangement of the
macrocycle.

Conclusions

In this paper, we have reported the syntheses and characterisation of bromo-alkyl derivatives of
2,6-bis(tetrazole)pyridine, where the alkyl chain contains either 3, 5, 7 or 9 carbons atoms.
Interestingly, the predominant compound formed in these reactions is the asymmetric 1-N,2-N’bistetrazole isomer, whereas the same reactions carried out with 1,3-bis(tetrazole)benzene have
previously yielded symmetric 2-N,2-N’-bistetrazole derivatives. Four new tetra-tetrazole
macrocycles, containing one pyridine ring, were synthesised and the X-ray crystal structure of
10

one such macrocycle (7c) showed a bowl-shaped conformation. Complexation studies of these
new tetra-tetrazole macrocycles with various metal ions are currently being undertaken.

Experimental

All reagents and solvents were commercially obtained and used without further purification. The
petroleum ether used for chromatography was 40:60 reagent grade. 1H and

13

C NMR (δ ppm; J

Hz) spectra were recorded on a JEOL JNM-LA300 FT-NMR spectrometer using saturated CDCl3
solutions with Me4Si reference, unless indicated otherwise. Infrared spectra (cm-1) were recorded
as KBr discs or liquid films between KBr plates using a Nicolet Impact 410 FT-IR
spectrophotometer. Melting point analysis was carried out using either a Stewart Scientific SMP1
or a Mettler FP62 melting point apparatus and are uncorrected. Microanalysis was carried out at
the Microanalytical Laboratory of University College, Dublin. Mass spectrometry was carried out
at the Centre for Synthesis and Chemical Biology (CSCB), University College, Dublin using
Quattro microTM LC-MS/MS and LCT mass spectrometers. Standard Schlenk techniques were
used throughout. The synthesis of compounds 619 has been described previously.

CAUTION: Owing to their potentially explosive nature, all preparations of and subsequent
reactions with azides and tetrazoles were conducted under an inert atmosphere behind a rigid
safety screen.

Synthesis of 2,6-di(2H-tetrazol-5-yl)pyridine (2)

A suspension of 2,6-pyridinedicarbonitrile (2.57 g, 20 mmol), sodium azide (2.86 g, 43 mmol),
ammonium chloride (2.35 g, 43 mmol) and lithium chloride (0.6 g, 14 mmol) in anhydrous
dimethylformamide (60 mL) was stirred for 10 hours at 110 oC. After this time, the solution was
cooled and the insoluble salts were removed by filtration. The solvent was then evaporated under
reduced pressure and the residue was dissolved in deionised water (200 mL) and acidified with
concentrated HCl (3 mL), to initiate precipitation. The product was filtered, washed with water (3
x 40 mL) and dried to give 2,6-di(2H-tetrazol-5-yl)pyridine (2) as a white crystalline powder.
Purification by recrystallisation from methanol to give white needles of 2 (3.08 g, 14.3 mmol, 72
%); mp > 300 °C; IR (KBr cm-1) 3415 (N-H), 2851, 1654, 1596, 1458, 1278; 1H NMR (300
MHz, (CD3)2SO): δH 8.49 (1H, t, J = 7.8 Hz, ArH), 8.23 (2H, d, J = 7.6 Hz, ArH), 3.56 (2H, s
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(br), NH);
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C NMR (75.4 MHz, (CD3)2SO): δC 158.5, 145.5, 142.9, 119.3, 125.4. Anal. Calcd

for C7H5N9: C, 39.07; H, 2.34; N, 58.59%. Found C, 38.98; H, 2.36; N, 58.45%.
General Syntheses of alkylated bis-tetrazoles (3 & 4)

Compound 2 (1.51 g, 7.0 mmol) was dissolved in methanol (60 ml) and to the stirred solution
was added triethylamine (4.23 ml, 42 mmol). The resulting solution was stirred at reflux
temperature for 30 minutes, then to the hot solution was added the corresponding dibromoalkane
(21.0 mmol). The reaction mixture was then stirred at reflux for a further 24 hours. On cooling,
the solid was removed by filtration and the solvent was removed from the filtrate under vacuum.
The resulting products were purified by column chromatography on silica gel (initially @ a ratio
of petroleum ether:ethyl acetate 70:30, followed by the ratio 60:40).

2-[2-(3-Bromopropyl)-2H-tetrazol-5-yl]-6-[1-(3-bromopropyl)-1H-tetrazol-5-yl]pyridine (3a)

White solid (0.55 g, 1.2 mmol, 17.2 %); mp 88-90 °C; Rf = 0.32 (60:40 petroleum ether/ethyl
acetate); IR (KBr, cm-1): 2968, 1668 (>C=N-), 1523 (-N=N-), 1458 (C=N, pyridine), 1434, 1254;
1

H NMR (300 MHz, CDCl3): δH 2.67 (4H, m, CH2), 3.51 (2H, t, J = 6.1 Hz, CH2Br (N2)), 3.62

(2H, t, J = 6.6 Hz, CH2Br (N1)), 4.96 (2H, t, J = 6.6 Hz, CH2N2), 5.25 (2H, t, J = 6.7 Hz,
CH2N1), 8.12 (1H, t, J = 7.8 Hz, pyH), 8.38 (1H, d, J = 7.8 Hz, pyH), 8.50 (1H, d, J = 7.8 Hz,
pyH);
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C NMR (75.4 MHz, CDCl3): δC 28.7, 29.3, 31.9, 32.9, 48.9, 51.6, 124.0, 125.3, 138.5,

145.0, 146.7, 151.4, 164.1. Anal. Calcd for C13H15N9Br2: C, 34.16; H, 3.31; N, 27.58%. Found:
C, 34.48; H, 3.44; N, 27.21%.

2,6-Bis[2-(3-bromopropyl)-2H-tetrazol-5-yl]-pyridine (4a)
White solid (0.10 g, 0.22 mmol, 3.1 %); mp 94-96 °C; Rf = 0.21 (60:40 petroleum ether/ethyl
acetate); IR (KBr, cm-1): 2922, 2855, 1648 (>C=N-), 1587 (-N=N-), 1459 (C=N, pyridine), 1436,
1263; 1H NMR (300 MHz, CDCl3): δH 2.68 (4H, q, J = 6.1 Hz, CH2), 3.48 (4H, t, J = 6.8 Hz,
CH2Br), 4.95 (4H, t, J = 6.8 Hz, CH2N), 8.02 (1H, t, J = 7.8 Hz, pyH), 8.37 (2H, d, J = 7.8 Hz,
pyH); 13C NMR (75.4 MHz, CDCl3): δC 29.7, 31.8, 51.7, 123.8, 138.5, 148.3, 164.4. Anal. Calcd
for C13H15N9Br2: C, 34.16; H, 3.31; N, 27.58%. Found: C, 34.38; H, 3.24; N, 27.24%.
2-[2-(5-Bromopentyl)-2H-tetrazol-5-yl]-6-[1-(5-bromopentyl)-1H-tetrazol-5-yl]-pyridine (3b)
12

White solid (1.21 g, 2.36 mmol, 33.6 %); mp 78-80 °C; Rf = 0.41 (60:40 petroleum ether/ethyl
acetate); IR (KBr, cm-1): 2925, 2857, 1651 (>C=N-), 1582 (-N=N-), 1460 (C=N, pyridine), 1434,
1261; 1H NMR (300 MHz, CDCl3): δH 1.71 (4H, m, CH2), 1.93 (4H, m, CH2), 2.17 (4H, m, CH2),
3.42 (4H, m, CH2Br), 4.76 (2H, t, J = 7.1 Hz, CH2N2), 5.16 (2H, t, J = 7.8 Hz, CH2N1), 8.12
(1H, t, J = 7.8 Hz, pyH), 8.36 (1H, d, J = 6.9 Hz, pyH), 8.49 (1H, d, J = 6.9 Hz, pyH); 13C NMR
(75.4 MHz, CDCl3): δC 25.0, 26.4, 27.2, 27.9, 28.6, 28.9, 29.7, 32.9, 49.8, 53.3, 123.9, 125.2,
138.8, 145.2, 146.9, 151.2, 164.0. Anal. Calcd for C17H23N9Br2: C, 39.78; H, 4.52; N, 24.56%.
Found: C, 39.83; H, 4.46; N, 24.53%.

2,6-Bis-[2-(5-bromopentyl)-2H-tetrazol-5-yl]-pyridine (4b)

White solid (0.10 g, 0.2 mmol, 2.8 %); mp 82-84 °C; Rf = 0.32 (60:40 petroleum ether/ethyl
acetate); IR (KBr, cm-1): 2926, 2856, 1649 (>C=N-), 1581 (-N=N-), 1462 (C=N, pyridine), 1435,
1258; 1H NMR (300 MHz, CDCl3): δH 1.68 (4H, m, CH2), 1.91 (4H, m, CH2), 2.19 (4H, m, CH2),
3.41 (4H, t, J = 6.6 Hz, CH2Br), 4.77 (4H, t, J = 7.1 Hz, CH2N), 8.06 (1H, t, J = 7.8 Hz, pyH),
8.45 (2H, d, J = 7.8 Hz, pyH);
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C NMR (75.4 MHz, CDCl3): δC 28.0, 28.2, 28.5, 31.8, 53.2,

123.6, 138.4, 147.5, 164.3. Anal. Calcd for C17H23N9Br2: C, 39.78; H, 4.52; N, 24.56%. Found:
C, 39.79; H, 4.54; N, 24.51%.

2-[2-(7-Bromoheptyl)-2H-tetrazol-5-yl]-6-[1-(7-bromoheptyl)-1H-tetrazol-5-yl]-pyridine (3c)

White solid (1.32 g, 2.32 mmol, 33 %); mp 64-66 °C; Rf = 0.53 (60:40 petroleum ether/ethyl
acetate); IR (KBr, cm-1): 2923, 2857, 1653 (>C=N-), 1581 (-N=N-), 1464 (C=N, pyridine), 1434,
1261; 1H NMR (300 MHz, CDCl3): δH 1.41 (12H, m, CH2), 1.83 (4H, m, CH2), 2.09 (4H, m,
CH2), 3.40 (4H, m, CH2Br), 4.73 (2H, t, J = 7.1 Hz, CH2N2), 5.14 (2H, t, J = 7.4 Hz, CH2N1),
8.10 (1H, t, J = 7.8 Hz, pyH), 8.36 (1H, d, J = 6.8 Hz, pyH), 8.48 (1H, d, J = 6.8 Hz, pyH); 13C
NMR (75.4 MHz, CDCl3): δC 26.1, 26.2, 27.8, 27.9, 28.1, 28.2, 29.3, 30.0, 32.5, 32.6, 33.8, 33.9,
50.1, 53.5, 123.8, 125.1, 138.8, 145.2, 146.9, 151.2, 164.0. Anal. Calcd for C21H31N9Br2: C,
44.30; H, 5.49; N, 22.14%. Found: C, 44.36; H, 5.54; N, 22.17%.

2,6-Bis-[2-(7-bromoheptyl)-2H-tetrazol-5-yl]-pyridine (4c)
White solid (0.20 g, 0.35 mmol, 5 %); mp 70-72 °C; Rf = 0.43 (60:40 petroleum ether/ethyl
acetate); IR (KBr, cm-1): 2928, 2856, 1653 (>C=N-), 1581 (-N=N-), 1463 (C=N, pyridine), 1430,
13

1260; 1H NMR (300 MHz, CDCl3): δH 1.37 (12H, m, CH2), 1.89 (4H, m, CH2), 2.11 (4H, m,
CH2), 3.44 (4H, t, J = 7.3 Hz, CH2Br), 4.76 (4H, t, J = 7.3 Hz, CH2N), 8.12 (1H, t, J = 7.7 Hz,
pyH), 8.36 (2H, d, J = 7.8 Hz, pyH);
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C NMR (75.4 MHz, CDCl3): δC 27.2, 28.6, 28.7, 29.8,

32.7, 34.1, 53.6, 123.5, 138.3, 147.6, 164.2. Anal. Calcd for C21H31N9Br2: C, 44.30; H, 5.49; N,
22.14%. Found: C, 44.26; H, 5.44; N, 22.09%.
2-[2-(9-Bromononyl)-2H-tetrazol-5-yl]-6-[1-(9-bromononyl)-1H-tetrazol-5-yl]-pyridine (3d)

White solid (1.61 g, 2.6 mmol, 36.7 %); mp 51-53 °C; Rf = 0.67 (60:40 petroleum ether/ethyl
acetate); IR (KBr, cm-1): 2923, 2857, 1653 (>C=N-), 1581 (-N=N-), 1464 (C=N, pyridine), 1434,
1261; 1H NMR (300 MHz, CDCl3): δH 1.34 (12H, m, CH2), 1.61 (8H, m, CH2), 1.83 (4H, m,
CH2), 2.08 (4H, m, CH2), 3.40 (4H, m, CH2Br), 4.72 (2H, t, J = 7.1 Hz, CH2N2), 5.16 (2H, t, J =
7.3 Hz, CH2N1), 8.09 (1H, t, J = 8.1 Hz, pyH), 8.36 (1H, d, J = 7.8 Hz, pyH), 8.48 (1H, d, J = 7.8
Hz, pyH);
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C NMR (75.4 MHz, CDCl3): δC 24.7, 24.8, 24.9, 25.0, 25.1, 25.1, 25.2, 25.3, 25.3,

25.4, 25.5, 26.4, 27.2, 28.9, 28.1, 29.7, 32.9, 49.7, 53.3, 123.9, 125.2, 138.7, 145.4, 146.8, 151.3,
164.4. Anal. Calcd for C25H39N9Br2: C, 48.01; H, 6.29; N, 20.16%. Found: C, 48.06; H, 6.28; N,
20.19%.

2,6-Bis-[2-(9-bromononyl)-2H-tetrazol-5-yl]-pyridine (4d)
White solid (0.20 g, 0.3 mmol, 4.6 %); mp 58-60 °C; Rf = 0.54 (60:40 petroleum ether/ethyl
acetate); IR (KBr, cm-1): 2925, 2855, 1651 (>C=N-), 1582 (-N=N-), 1460 (C=N, pyridine), 1434,
1261; 1H NMR (300 MHz, CDCl3): δH 1.37 (16H, m, CH2), 1.61 (4H, m, CH2), 1.89 (4H, m,
CH2), 2.11 (4H, m, CH2), 3.40 (4H, t, J = 7.1 Hz, CH2Br), 4.72 (4H, t, J = 7.1 Hz, CH2N), 8.12
(1H, t, J = 7.7 Hz, pyH), 8.36 (2H, d, J = 7.8 Hz, pyH); 13C NMR (75.4 MHz, CDCl3): δC 26.3,
26.8, 27.2, 28.6, 28.7, 29.8, 32.7, 34.0, 53.5, 123.5, 138.3, 147.6, 164.2. Anal. Calcd for
C25H39N9Br2: C, 48.01; H, 6.29; N, 20.16%. Found: C, 48.10; H, 6.32; N, 20.21%.
General Syntheses of di-pyridyl-tetra-tetrazole macrocycles (5a-d)
A mixture of 2 (0.86 g, 4.0 mmol) and potassium carbonate (2.78 g, 20.0 mmol) in anhydrous
dimethylformamide (50 ml) was stirred at 75 °C under a nitrogen atmosphere, then treated with
3a-d (4.0 mmol) and stirred at 75 °C for 24 hours. The insoluble salts, which were removed from
the cooled mixture by filtration, were washed with ethyl acetate. The combined washings and
mother-liquor were evaporated under reduced pressure. The residue was dissolved in chloroform
14

and chromatographed on a silica gel column using ethyl acetate:petroleum ether (70:30 v/v) as
eluent to give a white solid. Only 1H NMR data was obtained for all mixtures.

Macrocycle 5a
1

H NMR (300 MHz, CDCl3): δH 1.97 (4H, br m, CH2), 4.75 (4H, br t, CH2N2), 5.27 (4H,br t,

CH2N1), 8.15 (2H, br t, pyH), 8.35 (2H, br d, pyH), 8.48 (2H, br d, pyH).
Macrocycle 5b
1

H NMR (300 MHz, CDCl3): δH 1.42 (8H, br m, CH2), 1.83 (4H, br m, CH2), 4.79 (4H, br t,

CH2N2), 5.23 (4H,br t, CH2N1), 8.14 (2H, br t, pyH), 8.33 (2H, br d, pyH), 8.50 (2H, br d, pyH).
Macrocycle 5c
1

H NMR (300 MHz, CDCl3): δH 1.45 (12H, br m, CH2), 1.79 (8H, br m, CH2), 4.72 (4H, br t,

CH2N2), 5.30 (4H, br t, CH2N1), 8.18 (2H, br t, pyH), 8.39 (2H, br d, pyH), 8.46 (2H, br d, pyH).
Macrocycle 5d
1

H NMR (300 MHz, CDCl3): δH 1.35 (12H, br m, CH2), 1.65 (8H, br m, CH2), 1.81 (8H, br m,

CH2), 4.73 (4H, br t, CH2N2), 5.12 (4H, br t, CH2N1), 8.09 (2H, br t, pyH), 8.04 (1H, d, J = 6.8
Hz, pyH), 8.17 (2H, m, ArH), 8.31 (1H, d, J = 6.7 Hz, pyH), 8.41 (1H, s, ArH).

General Syntheses of pyridyl-tetra-tetrazole macrocycles (7a-d)

A mixture of 6 (0.86 g, 4.0 mmol) and potassium carbonate (2.78 g, 20.0 mmol) in anhydrous
dimethylformamide (50 ml) was stirred at 75 °C under a nitrogen atmosphere, then treated with
3a-d (4.0 mmol) and stirred at 75 °C for 24 hours. The insoluble salts, which were removed from
the cooled mixture by filtration, were washed with ethyl acetate. The residue was dissolved in
chloroform and chromatographed on a silica gel column using ethyl acetate:petroleum ether
(70:30 v/v) as eluent to give the pyridine tetra-tetrazolophane macrocycles (7a-d).
Macrocycle 7a
White crystalline solid (0.43 g, 0.84 mmol, 21 %); mp 210-212 °C; Rf = 0.03 (50:50 petroleum
ether/ethyl acetate); IR (KBr, cm-1): 2926, 2851, 1654 (>C=N-), 1596 (-N=N-), 1458 (C=N,
pyridine), 1433, 1261; 1H NMR (300 MHz, CDCl3): δH 1.67 (4H, m, CH2), 4.74 (2H, m, CH2N2),
5.03 (4H, m, CH2N2), 5.30 (2H, t, J = 7.1 Hz, CH2N1), 7.60 (1H, t, J = 7.6 Hz, ArH), 7.91 (1H, t,
J = 7.9 Hz, pyH), 8.04 (1H, d, J = 6.8 Hz, pyH), 8.17 (2H, m, ArH), 8.31 (1H, d, J = 6.7 Hz,
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pyH), 8.41 (1H, s, ArH);
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C NMR (75.4 MHz, CDCl3): δC 29.4, 29.7, 46.1, 49.4, 50.4, 51.3,

123.9, 125.7, 125.8, 127.8, 128.1, 128.2, 128.8, 129.8, 138.7, 144.5, 146.8, 151.5, 163.9, 164.2,
164.6; HRMS (M+H)+ calcd for C21H20N17 = 510.2009, found = 510.2085. Anal. Calcd for
C21H19N17: C, 49.51; H, 3.76; N, 46.74%. Found: C, 49.62; H, 3.88; N, 46.91%.
Macrocycle 7b
White crystalline solid (0.45 g, 0.79 mmol, 20 %); mp 195-197 °C; Rf = 0.16 (50:50 petroleum
ether/ethyl acetate); IR (KBr, cm-1): 2925, 2855, 1654 (>C=N-), 1596 (-N=N-), 1458 (C=N,
pyridine), 1433, 1261; 1H NMR (300 MHz, CDCl3): δH 1.64 (4H, m, CH2), 2.19 (8H, m, CH2),
4.74 (6H, m, CH2N2), 5.10 (2H, t, J = 7.2 Hz, CH2N1), 7.68 (1H, t, J = 7.8 Hz, ArH), 7.94 (1H, t,
J = 7.9 Hz, pyH), 8.13 (1H, d, J = 6.8 Hz, pyH), 8.31 (2H, m, ArH), 8.40 (1H, d, J = 6.8 Hz,
pyH), 8.69 (1H, s, ArH);
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C NMR (75.4 MHz, CDCl3): δC 23.4, 23.5, 28.1, 28.3, 28.8, 29.4,

49.7, 52.3, 53.0, 53.1, 123.8, 125.2, 125.5, 128.0, 128.2, 128.3, 128.4, 129.7, 138.6, 145.0, 146.7,
151.4, 164.0, 164.2, 164.6; HRMS (M+H)+ calcd for C25H28N17 = 566.2635, found = 566.2695.
Anal. Calcd for C25H27N17: C, 53.09; H, 4.81; N, 42.10%. Found: C, 52.89; H, 4.71; N, 42.54%.
Macrocycle 7c
White crystalline solid (0.43 g, 0.69 mmol, 17.3 %); mp 185-187 °C; Rf = 0.35 (50:50 petroleum
ether/ethyl acetate); IR (KBr, cm-1): 2924, 2855, 1658 (>C=N-), 1597 (-N=N-), 1459 (C=N,
pyridine), 1432, 1261; 1H NMR (300 MHz, CDCl3): δH 1.43 (10H, m, CH2), 2.08 (10H, m, CH2),
4.70 (6H, m, CH2N2), 5.10 (2H, t, J = 7.2 Hz, CH2N1), 7.64 (1H, t, J = 7.7 Hz, ArH), 8.04 (1H, t,
J = 7.9 Hz, pyH), 8.25 (1H, d, J = 7.0 Hz, pyH), 8.32 (2H, m, ArH), 8.44 (1H, d, J = 6.9 Hz,
pyH), 8.83 (1H, s, ArH);

13

C NMR (75.4 MHz, CDCl3): δC 25.6, 25.8, 26.1, 26.2, 27.6, 28.4,

28.8, 29.2, 29.7, 29.9, 49.9, 52.8, 53.2, 53.4, 123.8, 125.2, 125.3, 128.2, 128.3, 128.4, 128.5,
129.7, 138.7, 145.2, 146.9, 151.3, 163.9, 164.4, 164.6; HRMS (M+H)+ calcd for C29H36N17 =
622.3261, found = 622.3317. Anal. Calcd for C29H35N17: C, 56.03; H, 5.67; N, 38.30%. Found:
C, 56.34; H, 5.83; N, 38.19%.
Macrocycle 7d
White crystalline solid (0.41 g, 0.61 mmol, 15 %); mp 167-168 °C; Rf = 0.58 (50:50 petroleum
ether/ethyl acetate); IR (KBr, cm-1): 2920, 2852, 1656 (>C=N-), 1596 (-N=N-), 1459 (C=N,
pyridine), 1434, 1260; 1H NMR (300 MHz, CDCl3): δH 1.33 (22H, m, CH2), 2.07 (10H, m, CH2),
4.69 (6H, m, CH2N2), 5.12 (2H, t, J = 7.3 Hz, CH2N1), 7.64 (1H, t, J = 7.2 Hz, ArH), 8.07 (1H, t,
J = 7.8 Hz, pyH), 8.29 (3H, m, pyH & ArH), 8.46 (1H, d, J = 6.9 Hz, pyH), 8.89 (1H, s, ArH);
13

C NMR (75.4 MHz, CDCl3): δC 25.8, 26.1, 28.3, 28.4, 28.7, 28.8, 28.9, 29.0, 29.1, 29.2, 29.3,
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29.7, 30.3, 50.1, 53.1, 53.3, 53.5, 123.7, 125.1, 125.2, 128.3, 128.4, 129.6, 138.7, 145.2, 146.9,
151.3, 163.9, 164.4, 164.5; HRMS (M+H)+ calcd for C33H44N17 = 678.3887, found = 678.3944.
Anal. Calcd for C33H43N17: C, 58.48; H, 6.39; N, 35.13%. Found: C, 58.34; H, 6.43; N, 35.19%.
Crystallography
Data for 3b and 7c were collected at 150(2)K on a Bruker Apex II CCD diffractometer using
MoKα radiation (λ = 0.71073Å). The structures were solved by direct methods and refined on F2
using all the reflections.20 All the non-hydrogen atoms were refined using anisotropic atomic
displacement parameters and hydrogen atoms were inserted at calculated positions using a riding
model. Crystallographic data for 3b and 7c has been deposited with the Cambridge
Crystallographic Data Centre as supplementary publication number 799907 and 799908. Copies
of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge
CB2 1EZ, UK (Fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk).

Compound 3b. Crystal data: C17H23Br2N9, M = 513.26, orthorhombic, a = 9.99029(19), b =
10.2310(19), c = 40.898(8) Å, U = 4143.6(13) Å3, space group Pbca, Z = 8, μ = 3.936 mm-1, calc
= 1.646 Mg.cm–3. 28973 data (3639 unique, Rint = 0.1246) were measured in the range 1.99 < θ <
25.00˚. R1(I > 2σ(I)) = 0.0883 and wR2(all data) = 0.2113. Goodness of fit on F2 = 1.178. CCDC
No. 799907.

Compound 7c. Crystal data: C29H35N17, M = 621.74, monoclinic, a = 11.5821(13), b =
8.1191(9), c = 32.691(4) Å, β = 90.034(2)º, U = 3074.1(6) Å3, space group P21/c, Z = 4, μ =
0.090 mm-1, calc = 1.343 Mg.cm–3. 26150 data (6321 unique, Rint = 0.0478) were measured in the
range 1.76 < θ < 26.42˚. R1(I > 2σ(I)) = 0.0432 and wR2(all data) = 0.1087. Goodness of fit on F2
= 1.021. CCDC No. 799908.
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Synthesis and characterisation of macrocycles containing both tetrazole and
pyridine functionalities
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The

syntheses

of

tetra-tetrazole

macrocycles containing at least one
2,6-bis(tetrazole)pyridine unit, linked
by a variety of n-alkyl (n = 3, 5, 7 or 9
carbon atoms) chain lengths, are
described. There has been no previous
incorporation of the pyridine moiety
into a tetra-tetrazolophane macrocycle.
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